Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Non-small cell lung cancer
EGFR, ALK, KRAS G12C and the ADC wave in first and later lines.
ESMO Congress 2026
23–27 Oct 2026, Madrid · Annals of Oncology, vol. 37 supplement
The ESMO 2026 abstract supplement was not in Crossref on 11 Nov 2026 and ESMO's congress platform blocks automated access, so ESMO abstracts here come from web research: each row was found on a published congress report and verified against it.
Headline and verified abstracts
62 abstracts found by Parallel web research on 2026-11-11 and verified: 18 checked on the source page, 16 on a second source, 28 against the saved source excerpt. Rows that could not be verified were dropped. Titles and metadata only; abstract text is not stored.
- LBA5Presidential
- LBA6Presidential
- LBA62Late-breaking
- LBA64Late-breakingToripalimab plus chemotherapy as perioperative treatment for resectable stage II or III non-small cell lung cancer (NSCLC): Final analysis of the Phase 3 Neotorch studyShun LuNeotorchtoripalimabchemotherapyVerified on a second sourceliangyihui.net
- LBA65Late-breaking
- LBA66Late-breakingSacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 studyCaicun ZhouOptiTROP-Lung06sacituzumab tirumotecanpembrolizumabchemotherapyVerified on a second sourceliangyihui.net
- LBA67Late-breakingFinal OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 studyLi ZhangOptiTROP-Lung04sacituzumab tirumotecanplatinum-based chemotherapyVerified on a second sourceliangyihui.net
- LBA68Late-breakingPhase 3 study of sigvotatug vedotin (SV) vs docetaxel (DTX) in previously treated nonsquamous non-small cell lung cancer (NSCLC)Solange Peterssigvotatug vedotindocetaxelVerified on a second sourceliangyihui.net
- LBA69Late-breaking
- LBA71Late-breakingPANKU-Lung01: Randomized Phase III Study of Izalontamab Brengitecan (iza-bren) in EGFR-Mutant Non-squamous Non‑Small Cell Lung Cancer (NSCLC) After Progression on a Third Generation EGFR TKILi ZhangPANKU-Lung01izalontamab brengitecanVerified on a second sourceliangyihui.net
- LBA72Late-breakingRuzaltatug rezetecan, a HER3-directed ADC, vs platinum-based chemotherapy (PBC) in EGFR-mutated advanced NSCLC progressing after EGFR-TKI: interim analyses (IA) from the phase 3 HERON-Lung01 trialYi-Long WuHERON-Lung01ruzaltatug rezetecanplatinum-based chemotherapyVerified on a second sourceliangyihui.net
- LBA73Late-breakingPACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line treatment (AIO-TRK-0422/ass)Martin SebastianPACE-LUNGosimertinibchemotherapyVerified on a second sourcecslide.ctimeetingtech.com
- LBA74Late-breakingFirst-line (1L) trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant (HER2m) NSCLC: patient-reported outcomes (PROs) from DESTINY-Lung04 (DL-04)DESTINY-Lung04 (DL-04)trastuzumab deruxtecanVerified on a second sourceliangyihui.net
- LBA75Late-breakingDeulorlatinib (TGRX‑326) vs crizotinib in TKI-naive advanced ALK+ NSCLC: a phase 3 studydeulorlatinibcrizotinibVerified on a second sourceliangyihui.net
- LBA76Late-breakingA global phase 2, open-label trial of pumitamig (PD-L1 × VEGF-A bsAb) + docetaxel post-chemoimmunotherapy in mNSCLC: first data from ROSETTA Lung-107ROSETTA Lung-107pumitamigdocetaxelMatches source excerptliangyihui.net
- 2511OOral presentationFinal analysis of adjuvant pembrolizumab (pembro) in resected early-stage non–small-cell lung cancer (NSCLC): Phase 3 PEARLS/KEYNOTE-091 studyPEARLS/KEYNOTE-091pembrolizumabVerified on source pageoncoletter.ch
- 2519OOral presentationAssociation of biomarkers with efficacy in the phase 3 KEYNOTE-671 study of perioperative pembrolizumab (Pembro) plus neoadjuvant chemotherapy (Chemo) in early-stage non–small-cell lung cancer (NSCLC)KEYNOTE-671pembrolizumabchemotherapyVerified on source pageoncoletter.ch
- 2613OOral presentation
- 2614OOral presentationPembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC with PD-L1 ≥50%: PERSEE phase 3 trial (GFPC 01-2020)PERSEE (GFPC 01-2020)pembrolizumabplatinum-based chemotherapyVerified on source pageoncoletter.ch
- 1950RORapid oral
- 2615RORapid oralDalmelitinib plus Aumolertinib versus platinum-based chemotherapy in advanced NSCLC patients with MET amplification post EGFR TKI: a randomized, phase 3 studydalmelitinibaumolertinibplatinum-based chemotherapyVerified on source pageioncology.com.cn
- 2616RORapid oral
- 2617RORapid oral
- 2618RORapid oralAnalysis of the phase 2 part of IFCT-2103 DIAL phase 2-3 randomized trial, comparing continuation pembrolizumab (± pemetrexed) up to 2 years versus observation (± pemetrexed), in patients with metastatic Non-Small Cell Lung Cancer (mNSCLC) with disease control (DC) at 6 monthsIFCT-2103 DIALpembrolizumabpemetrexedVerified on source pageioncology.com.cn
- 2631RORapid oralFirst-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 studyBAT8008BAT1308Verified on source pageoncoletter.ch
- 2636RORapid oral
- 2646RORapid oralA phase 2 trial of JS207 (PD-1/VEGF bispecific antibody) plus chemotherapy as first-line therapy for advanced non-small cell lung cancer (NSCLC)JS207chemotherapyVerified on source pageioncol.com
- 2658RORapid oralOverall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human studytelisotuzumab adizutecanVerified on source pageoncoletter.ch
- 2700RORapid oral
- 2719RORapid oralFLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)FLAURA2osimertinibplatinum–pemetrexedVerified on source pageoncoletter.ch
- 4247RORapid oralImmunogenomic signature associated with ICI-related pneumonitis in non-small cell lung cancer (NSCLC) patientsJarushka NaidooVerified on a second sourcecslide.ctimeetingtech.com
- 209PPosterAI-driven quantification of PD-L1 tumor proportion score (TPS) from immunohistochemistry slides in non-small cell lung cancer (NSCLC)Ana D. Ramos GuerraMatches source excerptcslide.ctimeetingtech.com
- 358PPosterMultimodal [18F]FDG-PET/CT foundation model framework for 24-month overall survival prediction in immunotherapy-treated advanced NSCLCBeshoy Guirges (presented by Rebecca Romanò)Matches source excerptcslide.ctimeetingtech.com
- 2515PPoster
- 2528PPosterReal-world outcomes of neoadjuvant and perioperative chemoimmunotherapy in resectable NSCLC: First analysis from “NeoReal study”Federica BertoliniNeoReal studynivolumabdurvalumabpembrolizumabMatches source excerptcslide.ctimeetingtech.com
- 2535PPoster
- 2536PPoster
- 2539PPosterClinical outcomes and recurrence patterns in early-stage fusion-positive NSCLC treated with initial surgery or SBRT: A retrospective institutional analysisAlexander Drilon (presented by Jaime Rubio Perez)Matches source excerptcslide.ctimeetingtech.com
- 2540PPoster
- 2543PPosterImpact of STAS and type of surgical resection in stage I lung adenocarcinomaMaria Alameda-GuijarroMatches source excerptcslide.ctimeetingtech.com
- 2546PPosterPreferences for adjuvant immunotherapy (AIT) after resection of NSCLC in BR.31: What survival benefits would make it worthwhile to participants (pts)?Kristin WrightBR.31durvalumabplaceboMatches source excerptcslide.ctimeetingtech.com
- 2547PPoster
- 2548PPoster
- 2573PPosterImneskibart (AU-007) + low-dose SC IL-2 + avelumab: Phase 2 activity in CPI-refractory advanced adenocarcinoma NSCLCimneskibart (AU-007)low-dose SC IL-2avelumabVerified on source pageaulosbio.com
- 2577PPoster
- 2583PPoster
- 2588PPosterMulticentre real-world analysis of predictors of survival after neoadjuvant immunochemotherapy in locally resectable non-small cell lung cancer (KOMPASS neo OP)Martin FaehlingKOMPASS neo OPMatches source excerptcslide.ctimeetingtech.com
- 2592PPosterDynamic cytokine profiling suggests an association between IP-10 and progression-free survival in locally advanced NSCLC treated with durvalumab after chemoradiotherapySaima J. FarooqiDARTdurvalumabMatches source excerptcslide.ctimeetingtech.com
- 2627PPoster
- 2636PPoster
- 2656PPoster
- 2660PPoster
- 2669PPoster
- 2676PPosterUpdated real-world outcomes with first-line lorlatinib in ALK-positive advanced NSCLC in Japan: ROYAL study second interim analysisROYALlorlatinibVerified on source pagecdn.pfizer.com
- 2688PPoster
- 2694PPoster
- 2696PPosterMolecular profile, treatment patterns, and real-world outcomes in HER2-mutant NSCLC: Results from the AACR project GENIE registryKenneth Kehl (presented by Brian Piening)Matches source excerptcslide.ctimeetingtech.com
- 2697PPoster
- 2702PPosterRET fusion–positive non-small cell lung cancer (NSCLC): Real-world data from the Italian ATLAS registryMaria Lucia RealeMatches source excerptcslide.ctimeetingtech.com
- 2711PPosterIntracranial progression-free survival with ivonescimab-based therapy in advanced NSCLC with baseline brain metastasesDaniel T. JonesHARMONi-A; HARMONi-2; HARMONi-6ivonescimabMatches source excerptcslide.ctimeetingtech.com
- 4161PPoster
- 4421PPosterSystemic inflammation and IL-1 signalling in EGFR-mutated non-small cell lung cancer treated with first-line osimertinibAndrea De Giglio (presented by Alessandro Di Federico)osimertinibMatches source excerptcslide.ctimeetingtech.com
Indexed in Crossref
The ESMO Congress 2026 supplement (Annals of Oncology, vol. 37 supplement) was not in Crossref when last checked on 11 Nov 2026. The verified abstracts above come from web research instead.